For at least four years, semaglutide can help non-diabetic adults who are overweight lose weight and manage their heart health problems.

Published Date: 15 May 2024

At this year's European Congress on Obesity (ECO) in Venice, Italy (12–15 May), two studies based on the seminal Semaglutide and Cardiovascular Outcomes (SELECT) trial by the same international author will be presented.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot